Parathyroid Disorders Market Research Report- Global Forecast to 2023

Parathyroid Disorders Market Size, Application And Trends Analysis By Type (Hyperparathyroidism, Parathyroid Cancer, Hypoparathyroidism), Diagnosis (Blood Test, Imaging, Urine Test), Treatment (Surgery, Radiation Therapy, Drugs), End User – Global Forecast Till 2023

ID: MRFR/Pharma/4005-HCR | February 2021 | Region: Global | 85 pages

Market Scenario:
Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.
According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.
Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.
Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the global parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.
Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.
Research Methodology:
 
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience:

Pharmaceutical Companies
Research and Development (R&D) Companies
Medical Device Companies
Diagnostic Laboratories
Government Research Institute
Academic Institutes and Universities

Segmentation
The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.
On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.
On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.
On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis:
The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.
The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Key Players
Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.



Frequently Asked Questions (FAQ) :


The the parathyroid disorder market obstacles are lack of funding, poor healthcare system in under-developed regions, side-effects, anomalies in drug market, and others.

parathyroid disorder market CAGR would be 6.5% during the forecast period.

By treatment, the parathyroid disorder market segments are surgery, radiation therapy, drugs, and others.

The Americas would dominate the parathyroid disorder market.

The parathyroid disorder market segments based on diagnosis are blood test, imaging test, and urine test.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Parathyroid Disorders Market, by Type

6.1 Introduction

6.2 Simple Parathyroid Disorders

6.2.1 Market Estimates & Forecast, 2017 – 2023

6.3 Complex Parathyroid Disorders

6.3.1 Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Parathyroid Disorders Market, by Diagnosis

7.1 Introduction

7.2 Physical Examination

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 Laboratory Tests

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 Electroencephalogram (EEG)

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Others

7.5.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Parathyroid Disorders Market, by treatment

8.1 Introduction

8.2 Home Management

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Antipyretic Medication

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Others

8.4.1 Market Estimates & Forecast, 2017 – 2023

Chapter 9. Global Parathyroid Disorders Market, by Distribution Channel

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2017 – 2023

9.3 Clinics

9.3.1 Market Estimates & Forecast, 2017 – 2023

9.4 Diagnostic Centers

9.4.1 Market Estimates & Forecast, 2017 – 2023

9.5 Drug Stores

9.5.1 Market Estimates & Forecast, 2017 – 2023

9.6 Pharmacies

9.6.1 Market Estimates & Forecast, 2017 – 2023

9.7 Others

9.7.1 Market Estimates & Forecast, 2017 – 2023

Chapter 10. Global Parathyroid Disorders Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Abbott Laboratories

12.1.1 Company Overview

12.1.2 Types Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Alcon Laboratories, Inc.

12.2.1 Company Overview

12.2.2 Types Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Amgen Inc.

12.3.1 Company Overview

12.3.2 Types Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Bayer Healthcare

12.4.1 Company Overview

12.4.2 Types/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Becton, Dickinson and Company

12.5.1 Company Overview

12.5.2 Types Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Eli Lilly

12.6.1 Company Overview

12.6.2 Types Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Ethicon, Inc.

12.7.1 Overview

12.7.2 Types Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Parathyroid Disorders industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Parathyroid Disorders Industry Synopsis, 2017 – 2023

Table 2 Parathyroid Disorders Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Parathyroid Disorders Market by Region, 2017 – 2023, (USD Million)

Table 4 Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 5 Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 6 Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 8 North America Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 9 North America Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 12 US Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 13 US Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 US Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 16 Canada Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 17 Canada Parathyroid Disorders market by Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Parathyroid Disorders market by End User, 2017 – 2023, (USD Million)

Table 20 South America Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 21 South America Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 22 South America Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 24 Europe Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 25 Europe Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 28 Western Europe Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 29 Western Europe Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Parathyroid Disorders market by Diagnosis, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Parathyroid Disorders Market by End User, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Parathyroid Disorders market by End User, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Parathyroid Disorders Market by Type, 2017 – 2023, (USD Million)

Table 41 Middle East & Africa Parathyroid Disorders Market by Diagnosis, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Parathyroid Disorders Market by Treatment, 2017 – 2023, (USD Million)

Table 43 Middle East & Africa Parathyroid Disorders market by End User, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Parathyroid Disorders Market

Figure 3 Segmentation Market Dynamics for Parathyroid Disorders Market

Figure 4 Global Parathyroid Disorders market Share, by Type 2016

Figure 5 Global Parathyroid Disorders market Share, by Diagnosis 2016

Figure 6 Global Parathyroid Disorders market Share, by Treatment 2016

Figure 7 Global Parathyroid Disorders market Share, by End User, 2016

Figure 8 Global Parathyroid Disorders market Share, by Region, 2016

Figure 9 North America Parathyroid Disorders market Share, by Country, 2016

Figure 10 Europe Parathyroid Disorders market Share, by Country, 2016

Figure 11 Asia Pacific Parathyroid Disorders market Share, by Country, 2016

Figure 12 Middle East & Africa Parathyroid Disorders market Share, by Country, 2016

Figure 13 Global Parathyroid Disorders market: Company Share Analysis, 2016 (%)

Figure 14 Abbott Laboratories: Key Financials

Figure 15 Abbott Laboratories Segmental Revenue

Figure 16 Abbott Laboratories: Geographical Revenue

Figure 17 Alcon Laboratories, Inc.: Key Financials

Figure 18 Alcon Laboratories, Inc.: Segmental Revenue

Figure 19 Alcon Laboratories, Inc.: Geographical Revenue

Figure 20 Amgen Inc.: Key Financials

Figure 21 Amgen Inc.: Segmental Revenue

Figure 22 Amgen Inc.: Geographical Revenue

Figure 23 Bayer Healthcare: Key Financials

Figure 24 Bayer Healthcare: Segmental Revenue

Figure 25 Bayer Healthcare: Geographical Revenue

Figure 26 Becton, Dickinson and Company: Key Financials

Figure 27 Becton, Dickinson and Company: Segmental Revenue

Figure 28 Becton, Dickinson and Company Geographical Revenue

Figure 29 Eli Lilly: Key Financials

Figure 30 Eli Lilly: Segmental Revenue

Figure 31 Eli Lilly: Geographical Revenue

Figure 32 Ethicon, Inc.: Key Financials

Figure 33 Ethicon, Inc.: Segmental Revenue

Figure 34 Ethicon, Inc.: Geographical Revenue